Risk of myocarditis and pericarditis following BNT162b2 and ChAdOx1 COVID-19 vaccinations

Authors

Samantha Ip, University of Cambridge
Fatemeh Torabi, Swansea University
Spiros Denaxas, University College London
Ashley Akbari, Swansea University
Hoda Abbasizanjani, Swansea University
Rochelle Knight, University of Bristol
Jennifer Cooper, University of Bristol
Rachel Denholm, University of Bristol
Spencer Keene, University of Cambridge
Thomas Bolton, Health Data Research UK
Sam Hollings, NHS Digital
Efosa Omigie, NHS Digital
Teri-Louise North, University of Bristol
Arun Karthikeyan Suseeladevi, University of Bristol
Emanuele Di Angelantonio, University of Cambridge
Kamlesh Khunti, University of Leicester
Jonathan A C Sterne, University of Bristol
Cathie Sudlow, University of Edinburgh
William Whiteley, University of Edinburgh
Angela Wood, University of Cambridge
Venexia Walker, University of Bristol

on behalf of the British Heart Foundation Data Science Centre (Health Data Research UK) CVD-COVID-UK/COVID-IMPACT Consortium and the Longitudinal Health and Wellbeing and Data and Connectivity UK COVID-19 National Core Studies

Abstract

We describe our analyses of data from over 49.7 million people in England, representing near-complete coverage of the relevant population, to assess the risk of myocarditis and pericarditis following BNT162b2 and ChAdOx1 COVID-19 vaccination. A self-controlled case series (SCCS) design has previously reported increased risk of myocarditis after first ChAdOx1, BNT162b2, and mRNA-1273 dose and after second doses of mRNA COVID-19 vaccines in England. Here, we use a cohort design to estimate hazard ratios for hospitalised or fatal myocarditis/pericarditis after first and second doses of BNT162b2 and ChAdOx1 vaccinations. SCCS and cohort designs are subject to different assumptions and biases and therefore provide the opportunity for triangulation of evidence. In contrast to the findings from the SCCS approach previously reported for England, we found evidence for lower incidence of hospitalised or fatal myocarditis/pericarditis after first ChAdOx1 and BNT162b2 vaccination, as well as little evidence to suggest higher incidence of these events after second dose of either vaccination.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Main text

On May 17th 2021, the US Centers for Disease Control and Prevention (CDC) reported mild to moderate myocarditis/pericarditis cases following a second dose mRNA COVID-19 vaccinations. Most patients were men <50 years old, presenting with chest pain, fever and raised cardiac-specific troponin several days after vaccination, followed by full recovery. A higher risk of myocarditis, particularly in younger men, was reported from Israel following second BNT162b2 vaccination. In England, a self-controlled case series (SCCS) design reported increased risks of myocarditis after first ChAdOx1, BNT162b2, and mRNA-1273 dose and after second doses of mRNA COVID-19 vaccines. Here, we use a cohort design to estimate adjusted hazard ratios (aHRs) for hospitalised or fatal myocarditis/pericarditis after first and second BNT162b2 and ChAdOx1 vaccinations. SCCS and cohort designs are subject to different assumptions and biases, so these results provide an opportunity for triangulation of evidence.

We analysed linked national electronic health records from multiple sources in England, including primary and secondary care, death registries, COVID-19 testing and vaccination data. Our analyses included up to 49,786,346 people aged 12+ years, of known sex, and alive at the start of the vaccination programme (December 8th 2020) with at least one primary care record. This corresponds to near-complete coverage of the relevant population. The outcomes ‘myocarditis’ and ‘pericarditis’ were defined using ICD10 codes (myocarditis: I40*,I41*,I51.4; pericarditis: I30*) recorded in any position for each hospital admission or cause of death. Outcome date was taken as the date of first relevant code and the combined outcome ‘myocarditis/pericarditis’ used the earliest date of either outcome. Follow-up began on December 8th 2020 for first dose analyses and on date of first vaccination for second dose analyses. Follow-up ended with the earliest of: outcome event, death, or study end date (May 17th 2021). Additionally, follow-up for first dose analyses ended at second vaccination with the same product or receipt of a non-BNT162b2 (for the BNT162b2 analysis) or non-ChAdOx1-S (for the ChAdOx1-S analysis) vaccination.

We estimated aHRs for hospitalised or fatal myocarditis/pericarditis 0-13 and 14+ days after first and second BNT162b2 and ChAdOx1-S vaccination using Cox models to account for calendar time. We adjusted for age, sex, region, socioeconomic status, ethnicity, prior COVID-19, and prior myocarditis/pericarditis. We examined interactions with sex and age group. For computational efficiency, we included all people with the outcome and a 10% random sample without the outcome. Inverse probability weights were used to account for sampling and confidence intervals derived using robust standard errors. To avoid ascertainment bias, follow-up ended on May 17th 2021, because clinicians aware of CDC reports may have lowered diagnostic thresholds in vaccinated compared with unvaccinated patients after that date. During this period, individuals aged 38+ years, along with the clinically vulnerable and frontline health and social care workers of any age, were eligible for vaccination. We replicated first dose analyses in Wales (N = 2,615,853) but had insufficient events to replicate other analyses. We performed two sensitivity analyses: (1) subgroup analysis in people with and without prior COVID-19 and (2) analysis of ‘myocarditis’ and ‘pericarditis’ separately collapsed into a single post-vaccination period. Our pre-specified protocol, code and additional analyses are publicly available (https://github.com/BHFDS/CCU002_03).

We identified 13,216,259 and 8,614,934 people who received first and second doses of BNT162b2; and 19,336,909 and 15,925,122 who received first and second doses of ChAdOx1. There were 1,459 events pre- and 607 events post-vaccination. We found lower incidence of myocarditis/pericarditis after first vaccination (0-13 days aHRs: BNT162b2 0.58, 95% CI 0.39-0.84; ChAdOx1-S 0.67, 95% CI 0.50-0.89, 14+ days aHRs: BNT162b2 0.80, 95% CI 0.65-0.97; ChAdOx1-S 0.75, 95% CI 0.63-0.90) compared with before or without vaccination. After second BNT162b2 vaccination the aHRs were: 0-13 days 0.77 (95% CI 0.50-1.18) and 14+ days 1.11 (95% CI 0.79-1.55) compared with the period between first and second doses. Corresponding aHRs following second ChAdOx1-S vaccination were 1.33 (95% CI 0.84-2.10) and 1.38 (95% CI 0.85-2.24). There was inconsistent evidence for interactions by sex and age group for second dose analyses (all heterogeneity p-values>=0.1), with low event counts preventing clear inferences. However, the aHRs for first dose analyses decreased with increasing age group. Subgroup analysis of
people with and without prior COVID-19 produced similar aHRs. Splitting the combined outcome suggested that pericarditis may be driving elevated aHRs (e.g., second ChAdOx1-S vaccination: pericarditis 2.04, 95% CI 1.12-3.70; myocarditis 1.24, 95% CI 0.75-2.04).

In contrast to the SCCS approach findings, we found evidence for lower incidence of hospitalised or fatal myocarditis/pericarditis after first ChAdOx1 and BNT162b2 vaccination. (3) Furthermore, we found little evidence to suggest higher incidence of these events after second dose of either vaccination. Myocarditis/pericarditis is rare after second BNT162b2 vaccination. Benefits of COVID-19 vaccination therefore substantially outweigh the risk of myocarditis/pericarditis.

References [5 maximum]


Funding

This work was supported by: the BHF Data Science Centre led by Health Data Research UK (BHF Grant no. SP/19/3/34678); the COVID-19 Longitudinal Health and Wellbeing National Core Study funded by the Medical Research Council [MC_PC_20030; MC_PC_20059]; the Con-COV team funded by the Medical Research Council (grant number: MR/V028367/1); Health Data Research UK (HDR-9006), which receives its core funding from the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation (BHF) and the Wellcome Trust; Health Data Research UK (HDR-9006), which receives its core funding from the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation (BHF) and the Wellcome Trust; the Wales COVID-19 Evidence Centre, funded by Health and Care Research Wales; the ADR Wales programme of work, which is aligned to the priority themes as identified in the Welsh Government’s national strategy, Prosperity for All, and brings together data science experts at Swansea University Medical School, staff from the Wales Institute of Social and Economic Research, Data and Methods (WISERD) at Cardiff University and specialist teams within the Welsh Government to develop new evidence which supports Prosperity for All by using the SAIL Databank at Swansea University, to link and analyse anonymised data. ADR Wales is part of the Economic and Social Research Council (part of UK Research and Innovation) funded ADR UK (grant ES/S007393/1). This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref: MC_PC_20058). SI was funded by the International Alliance for Cancer Early Detection, a partnership between Cancer Research UK C18081/A31373, Canary Center at Stanford University, the University of Cambridge, OHSU Knight Cancer Institute, University College London and the University of Manchester. VW was supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol [MC_UU_00011/4] and the National Core Studies, an initiative funded by UKRI, NIHR and the Health and Safety Executive.

Conflicts of interest

None.
Figure: Hazard ratio and 95% confidence interval for myocarditis/pericarditis following each dose of vaccine, by vaccine type.

### Dose 1
- **BNT162b2**: N = 49,786,346 with 13,216,259 exposed
- **ChAdOx1-S**: N = 49,786,346 with 19,366,909 exposed

### Dose 2
- **BNT162b2**: N = 13,216,259 with 8,614,934 exposed
- **ChAdOx1-S**: N = 19,366,909 with 15,925,122 exposed

#### By sex
- **Heterogeneity p-values**: BNT162b2, 0-13 p=0.04, 14+ p=0.87
  - ChAdOx1-S, 0-13 p=0.11, 14+ p=0.08

#### By age group
- **Heterogeneity p-values**: BNT162b2, 0-13 p<0.005, 14+ p<0.005
  - ChAdOx1-S, 0-13 p<0.005, 14+ p<0.005

### Days since vaccination
- **BNT162b2**
  - 0-13: 29 events, 162 events
  - 14+: 27 events, 72 events
- **ChAdOx1-S**
  - 0-13: 54 events, 215 events
  - 14+: 26 events, 22 events

- **Legend**:
  - ●: Overall
  - ▲: Sex: female
  - ■: Sex: male
  - ○: Age group: <40
  - △: Age group: 40-69
  - □: Age group: 70+
Hazard ratio and 95% confidence interval

Dose 1
BNT162b2, N = 49,786,346 with 13,216,259 exposed
ChAdOx1-S, N = 49,786,346 with 19,366,909 exposed

Overall

By sex

Heterogeneity p-values:
BNT162b2, 0-13 p<0.005, 14+ p<0.005
ChAdOx1-S, 0-13 p<0.005, 14+ p<0.005

By age group

Heterogeneity p-values:
BNT162b2, 0-13 p<0.005, 14+ p<0.005
ChAdOx1-S, 0-13 p<0.005, 14+ p<0.005

Dose 2
BNT162b2, N = 13,216,259 with 8,614,934 exposed
ChAdOx1-S, N = 19,366,909 with 15,925,122 exposed

Overall

By sex

Heterogeneity p-values:
BNT162b2, 0-13 p=0.90, 14+ p=0.62
ChAdOx1-S, 0-13 p=0.44, 14+ p=0.11

By age group

Heterogeneity p-values:
BNT162b2, 0-13 p=0.09, 14+ p=0.34
ChAdOx1-S, 0-13 p=0.10, 14+ p=0.76

Days since vaccination

BNT162b2
29 events 162 events
54 events 215 events

ChAdOx1-S
27 events 72 events
26 events 22 events

- BNT162b2
- Overall
- Sex: female
- Sex: male
- Age group: <40
- Age group: 40-69
- Age group: 70+